Effect of different progesterone timing on live birth rates following hatching blastocyst transfer in hormone replacement therapy cycles for frozen-warmed embryo transfer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600118889

Enrollment

Unknown

Registered

2026-02-12

Start date

2026-02-24

Completion date

Unknown

Last updated

2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

female infertility

Interventions

Group A:Hatching blastocysts are transferred after 6 days of progesterone supplementation

Group B:Hatching blastocysts are transferred after 7 days of progesterone supplementation

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Female age at the time of oocyte retrieval between 20 and 40 years. 2. Undergoing a hormone replacement therapy (HRT) cycle. 3. Single blastocyst transfer involving a hatching (stage 5) or hatched (stage 6) blastocyst. 4. According to the Gardner grading system and the 2025 ESHRE/Alpha Istanbul consensus, only patients whose planned transfer embryo was ranked as the highest-quality blastocyst (stage 5 or 6), or tied for highest quality, among the available embryos in that cycle were eligible. 5. Both partners fully understood the study and voluntarily agreed to participate.

Exclusion criteria

Exclusion criteria: 1. Recurrent pregnancy loss (>=2 spontaneous miscarriages). 2. Recurrent implantation failure (>=3 failed embryo transfer attempts). 3. Endometrial thickness =1 ng/mL on the day of progesterone initiation. 5. Presence of a "higher-quality" non-hatching blastocyst available for transfer. 6. Untreated hydrosalpinx. 7. Uterine abnormalities, including congenital uterine malformations, intrauterine adhesions, intrauterine fluid, adenomyosis, uterine fibroids, or endometrial polyps. 8. Hormone replacement therapy cycles with GnRH agonist pretreatment. 9. Presence of severe medical or surgical conditions contraindicating pregnancy. 10. Missing key data.

Design outcomes

Primary

Measure	Time frame
Live birth rate;	—

Secondary

Measure	Time frame
Biochemical pregnancy rate;Clinical pregnancy rate;Miscarriage rate;Ectopic pregnancy rate;Good birth outcome;Ongoing pregnancy rate;Gestational hypertension;Preeclampsia;Gestational diabetes mellitus;Preterm birth;Stillbirth;Birth weight;Congenital malformations;	—

Countries

China

Contacts

Public ContactRuiqiong Zhou

Reproductive medicine center of Guangdong Women and Children Hospital

zhouruiqiong123@163.com+86 182 1779 6656

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026